Fjarde AP Fonden Fourth Swedish National Pension Fund Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 44.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 459,443 shares of the company’s stock after purchasing an additional 140,700 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Teva Pharmaceutical Industries were worth $13,838,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. AQR Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after purchasing an additional 4,732 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the last quarter. Franklin Resources Inc. purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $255,000. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $238,000. Finally, Cerity Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries by 2.9% in the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after acquiring an additional 1,291 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TEVA shares. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. UBS Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Piper Sandler reaffirmed an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Stock Down 0.2%

TEVA stock opened at $34.55 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company’s 50-day moving average price is $33.96 and its 200 day moving average price is $32.55. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a market cap of $39.73 billion, a P/E ratio of 25.98, a P/E/G ratio of 4.23 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. The trade was a 34.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.